Oral Therapy for Infective Endocarditis: Where Do We Stand?

Fatima Allaw, Maya Dagher, Hiba Saliba, Jana Khalil, Souha S Kanj

Abstract readReview

In one paragraph

Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatima AllawDepartment of Internal Medicine, The View Hospital, Al Qutaifiya, Qatar.

Maya DagherDivision of Infectious Diseases, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0009-0006-7375-8447

Hiba SalibaDivision of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine American, University of Beirut, Beirut 1107 2020, Lebanon.

Jana KhalilDepartment of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.

Souha S KanjDivision of Infectious Diseases, Department of Internal Medicine, Faculty of Medicine American, University of Beirut, Beirut 1107 2020, Lebanon.ORCID 0000-0001-6413-3396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard therapy for infective endocarditis (IE) usually requires 4-6 weeks of intravenous (IV) antibiotics, ensuring sustained bactericidal concentrations, yet resulting in prolonged hospitalization and increased cost of care. These challenges have driven interest in oral antibiotic therapy (OAT) as a step-down strategy for selected, clinically stable patients. This review summarizes the clinical evidence and pharmacokinetic and pharmacodynamic (PK/PD) rationale and practical considerations supporting step-down OAT in IE. Antibiotics such as amoxicillin, fluoroquinolones, linezolid, and rifampicin have high bioavailability and maintain effective serum and tissue concentrations, and can be used as a safe transition from IV to oral therapy. The pivotal POET randomized controlled trial (RCT) demonstrated noninferiority of OAT compared with continued IV therapy in stable patients with left-sided IE caused by

Indexed as

Anti-Bacterial AgentsEndocarditisEndocarditis, BacterialAdministration, OralHumansAnti-Bacterial Agentsinfective endocarditisoral antibiotic therapyPOET trialstep-down oral therapy

Identifiers

PMID41471204

DOI10.3390/pathogens14121249

PMCPMC12735454

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.